Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Study casts fresh doubt on rosiglitazone

  • Comment
A study has found fresh evidence that the diabetes drug rosiglitazone is associated with an increased risk of congestive heart failure, acute myocardial infarction and mortality.

The retrospective study of 159,026 patients aged over 66 during a four year period showed rosiglitazone increased the risk of congestive heart failure by 60%, myocardial infarction by 40% and death by 29% compared with other oral hypoglycaemic agent combination therapies.

It also found that the risks did not occur in other thiazolidinediones, the group of drugs that rosiglitazone belongs to, which are used to treat type two diabetes.

In October, the European Medicines Agency acknowledged earlier reports that rosiglitazone and a similar drug, pioglitazone, increase the risk of MI but concluded that their benefits outweighed their hazards.

GlaxoSmithKline, which manufactures rosiglitazone under the trade name Avandia, hit back at the study.
A spokesperson said: ‘As the authors state, patients on TZDs in their analysis may represent an older, select group of patients with advanced diabetes and therefore higher baseline risk for cardiovascular disease.

‘When used in the appropriate patient, it [rosiglitazone] is an important treatment option for health-care professionals managing the chronic and life threatening disease of diabetes.’

Journal of the American Medical Association (2007) 298: 2634-2643
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.